Crispr Therapeutics AG stock kpis
Want to see CRSP full AI Analyst Report?
Revenue by Segment
In Q2 2026, Crispr Therapeutics AG reported revenue by segment of $10.00M (Collaboration) and $181.00K (Grant).
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Collaboration revenue is highly lumpy—driven by intermittent milestone/licensing payments that produced large spikes in 2021–2023 but fell back to near-zero in most quarters thereafter—so top-line visibility depends on timing of partner milestones. Grant revenue, by contrast, has become a small, steadier stream since late 2023, providing a modest cash cushion but not replacing collaboration variability. For investors, focus on upcoming partnership milestones, contract structures and cadence of milestones rather than quarterly trends; grants reduce some downside but won’t meaningfully smooth revenue.
CRSP Revenue by Segment
| Period | Collaboration | Grant |
|---|---|---|
| Q2 2026Jun 30, 2026 | $10.00M | $181.00K |
| Q1 2026Mar 31, 2026 | $1.00M | $458.00K |
| Q4 2025Dec 31, 2025 | $0.00 | $864.00K |
| Q3 2025Sep 30, 2025 | $0.00 | $889.00K |
| Q2 2025Jun 30, 2025 | $0.00 | $892.00K |
| Q1 2025Mar 31, 2025 | $0.00 | $865.00K |
| Q4 2024Dec 31, 2024 | $35.00M | $691.00K |
| Q3 2024Sep 30, 2024 | $0.00 | $602.00K |
| Q2 2024Jun 30, 2024 | $0.00 | $517.00K |
| Q1 2024Mar 31, 2024 | $0.00 | $504.00K |
| Q4 2023Dec 31, 2023 | $200.00M | $1.21M |
| Q3 2023Sep 30, 2023 | $0.00 | $0.00 |
| Q2 2023Jun 30, 2023 | $70.00M | $0.00 |
| Q1 2023Mar 31, 2023 | $100.00M | $0.00 |
| Q4 2022Dec 31, 2022 | $6.00K | $0.00 |
| Q3 2022Sep 30, 2022 | $94.00K | $0.00 |
| Q2 2022Jun 30, 2022 | $158.00K | $0.00 |
| Q1 2022Mar 31, 2022 | $178.00K | $762.00K |
| Q4 2021Dec 31, 2021 | $12.35M | $551.00K |
| Q3 2021Sep 30, 2021 | $329.00K | $495.00K |
| Q2 2021Jun 30, 2021 | $900.20M | $499.00K |
| Q1 2021Mar 31, 2021 | $202.00K | $337.00K |
| Q4 2020Dec 31, 2020 | $194.00K | $176.00K |
| Q3 2020Sep 30, 2020 | $148.00K | $0.00 |
| Q2 2020Jun 30, 2020 | $44.00K | $0.00 |
| Q1 2020Mar 31, 2020 | $157.00K | $0.00 |
| Q4 2019Dec 31, 2019 | $77.02M | $0.00 |
| Q3 2019Sep 30, 2019 | $211.93M | $0.00 |
| Q2 2019Jun 30, 2019 | $318.00K | $0.00 |
| Q1 2019Mar 31, 2019 | $328.00K | $0.00 |
| Q4 2018Dec 31, 2018 | $115.00K | $0.00 |
| Q3 2018Sep 30, 2018 | $563.00K | $0.00 |
| Q2 2018Jun 30, 2018 | $1.09M | $0.00 |
| Q1 2018Mar 31, 2018 | $1.36M | $0.00 |
| Q4 2017Dec 31, 2017 | $32.33M | $0.00 |
| Q3 2017Sep 30, 2017 | $2.39M | $0.00 |
| Q2 2017Jun 30, 2017 | $3.58M | $0.00 |
| Q1 2017Mar 31, 2017 | $2.70M | $0.00 |

